I am a
Home I AM A Search Login

Papers of the Week

Papers: 21 May 2022 - 27 May 2022


Human Studies, Pharmacology/Drug Development


2022 May 19

Sci Rep



Low adherence to the guideline for the acute treatment of migraine.


Olesen A, Winther Schytz H, Ostrowski S R, Topholm M, Nielsen K, Erikstrup C, Mikkelsen S, Pedersen O B, Olesen J, Hansen T F, Chalmer M A
Sci Rep. 2022 May 19; 12(1):8487.
PMID: 35589944.


The real-world use of triptans in the treatment of migraine is disappointing. Only 12% of the Danish migraine population purchased a triptan between 2014 and 2019, and only 43% repurchased a triptan after first prescription. The aim of the present study was to assess whether physicians and patients adhere to the therapeutic guideline on acute migraine treatment. We interviewed 299 triptan experienced participants with migraine and 101 triptan naïve participants with migraine from the Danish Migraine Population Cohort, using a semi-structured questionnaire. Descriptive statistical analyses were used to study the association with triptan use and the assessed factors. Among triptan naïve participants with migraine, 64% had consulted their general practitioner about their migraine, of whom only 23% received information about the possibility of triptan treatment. Among triptan experienced participants, 77% had only tried one type of triptan. Only 12% could recall they had been informed by their general practitioner to try each triptan three times before giving up. Twenty percent were informed to try three different triptans in total, if the first did not work. In disagreement with the guideline, participants who reported a low pain reduction by a triptan had only tried one type of triptan. Our study shows a low adherence to therapeutic guideline for the attack treatment of migraine. There is a need for better education of general practitioners regarding treatment of migraine. Future campaigns should aim to inform both the public and the general practitioner about antimigraine treatments.